Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 2, 2004, Pages 64-71

  Morgan, Trefor ^a,b   Anderson, Adrianne ^b   Bertram, Denise ^b   MacInnis, Robert Jeffrey ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

ACE inhibitors; Angiotensin; AT1 receptor blockers; Candesartan; Lisinopril; Microalbuminuria; Renin

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; PLACEBO;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALE; MICROALBUMINURIA; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; URINARY EXCRETION;

EID: 3543019104     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.012     Document Type: Article

References (24)

1. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
2. Gradman AH,Arcuri KE, Goldberg AL et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25:1345-50.
3. Lacourcière Y, Asmar R, for the Candesartan/Losartan Study Investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: A placebo-controlled, forced titration study. Am J Hypertens 1999;12:1181-7.
4. Wing LMH, Reid CM, Ryan P et al. for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
5. Dahlöf B, Devereux RB, Kheldsen SE et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003.
6. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:142-53.
7. Moldenhauer GK, Smith MD, Di Nicolantonio R, Doyle AE, Morgan TO. Angiotensins II and III prevent captopril-induced renin release in the rat. Clin Exp Pharmacol Physiol 1988;15: 113-21.
8. Morsing P, Adler G, Brandt-Eliasson U et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999;33:1406-13.
9. Vanderheyden PML, Fierens FLP, De Backer JP,Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hampster ovary cells expressing human angiotensin II type I receptors. Biochem Pharmacol 2000;59:927-35.
10. Mogensen CE, Neldam S, Tikkanen I et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
11. Morgan T, Griffiths C, Delbridge L. Interaction of ACE inhibitors and AT1-receptor blockers on maximum blood pressure response in spontaneous hypertensive rats. JRAAS 2002;3:16-18.
12. Morgan T, Griffiths C, Delbridge L. Low doses of angiotensin converting enzyme inhibitors and angiotensin Type 1 blockers have a synergistic effect but high doses are less than additive. Am J Hypertens 2002;15:1003-05.
13. van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998;98:73-81.
14. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57.
15. Sever PS, Chang CL. Discordant responses to two classes of drugs acting on the renin-angiotensin system. JRAAS 2001;2(1):25-30.
16. Morgan T, Anderson A. A comparison of candesartan, felodipine and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002; 15(6):544-9.
17. Morgan TO, Anderson A, Jones E. Comparison and interaction of low dose felodipine (ER) and enalapril in the treatment of essential hypertension in elderly patients. Am J Hypertens 1992;5:238-43.
18. Griffiths CD, Morgan TO, Delbridge LMD. Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake. J Hypertens 2001;19:2087-95.
19. Morgan T, Griffiths C, Delbridge L. Wall stress, angiotensin II and left ventricular hypertrophy. In: Epstein M, Brunner H, editors. Angiotensin II receptor antagonists. Philadelphia: Hanley & Belfus; 2000. p. 223-34.
20. McMurrary JVJ, Östergren J, Swedberg K et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
21. Rossing K, Jacobsen P, Pietraszek L, Parving H-H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003;26:2268-74.
22. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002;17:597-601.
23. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002;39:159-64.
24. Azizi M, Bissery A, Bura-Rivière A, Ménard J. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens 2003;21:1887-95.